苯并吡喃异黄酮化合物barbigerone干扰VEGF-D/VEGFR3信号通路抑制肿瘤淋巴管形成和转移的分子机制研究

基本信息
批准号:81374017
项目类别:面上项目
资助金额:60.00
负责人:万丽
学科分类:
依托单位:成都中医药大学
批准年份:2013
结题年份:2017
起止时间:2014-01-01 - 2017-12-31
项目状态: 已结题
项目参与者:李秀侠,胡佳,肖含,叶昊宇,陈翔,叶娜,罗红丽
关键词:
Barbigerone淋巴管形成肿瘤转移VEGFR3VEGRD
结项摘要

Metastases are responsible for the majority of cancer deaths in chemotherapy.Cancer cells spread through two important routes, including lymphatic or blood vessels. Comparing with hematogenous metastasis , lymphatic metastasis owns more advantages, however, related study received little attention until recently. We have isolated barbigerone (BA) from seeds of M. pachycarpa Benth. As a naturally occurring compound, besides apoptosis induction, it exhibits anti-angiogenesis activity in our reports. Further studies continued. In vivo, BA suppressed metastasis of B16 and VEGF-D/LL2 cells xenografts, with significant inhibition to lymphogenesis. Moreover, BA could inhibit migration and the formation of capillary-like structures of HLEC cells, decreased expression of VEGFR3 and the downstream protein kinases.It demonstrates that BA inhibits tumor lymphogenesis and matastases via regulating VEGF-D/VEGF3.In this study, we would focus on three parts: (1) We hope to demonstrate the specific machanisms of BA inhibiting the formation of lymphogenesis, and find the molecular networks of VEGFR3-FAK in lymphogenesis. (2) We will elucidate the molecular mechanisms in BA-mediated cancer cells migrarion and invasion. (3) VEGF-D/SKOV3 cells xenograft model was used to evaluate the inhibition of BA on tumor lymphogenesis and metastases in vivo.

肿瘤转移是化疗失败的主要原因之一。血管和淋巴管是肿瘤转移的两大通道,其中淋巴管转移有更多优势,但是该研究最近才被重视,相关药物开发有重要意义。Barbigerone (BA)是我们从厚果鸡血藤中获得的中药活性成分,该化合物诱导细胞凋亡和抗血管生成活性为我们首先报道。进一步研究,BA能显著抑制B16肿瘤转移和VEGF-D/LL2肿瘤淋巴管形成和转移;并能抑制细胞迁移和成管能力,降低VEGFR3及部分下游激酶的表达。揭示BA可能通过调节VEGF-D、VEGFR3相关信号通路抑制肿瘤淋巴管形成和转移。本课题重点研究以下三个方面:(1)揭示BA抑制淋巴管形成的具体作用机制,阐明FAK与VEGFR3的关系及其对淋巴管形成的调节作用;(2)研究BA抑制肿瘤细胞转移侵袭能力的分子调节机制;(3)建立人源VEGF-D/SKOV3移植瘤模型考察BA的药效。旨在为开发BA用于肿瘤治疗提供理论基础和研究新方向。

项目摘要

血管和淋巴管转移是肿瘤耐性性产生的两大机制,其中淋巴管转移的肿瘤更具有耐药性,但是相关的研究最近才被重视,该领域的药物研发具有重要意义。我们课题组在国家自然科学基金委的支持下完成了天然小分子抗肿瘤淋巴管转移的相关机制及药效研究,BA能显著抑制B16肿瘤转移和VEGF-D/LL2肿瘤淋巴管形成和转移;并能抑制细胞迁移和成管能力,降低VEGFR3及部分下游激酶的表达。揭示BA可能通过调节VEGF-D、VEGFR3相关信号通路抑制肿瘤淋巴管形成和转移。本课题主要进行了以下三个方面的研究:(1)揭示BA抑制淋巴管形成的具体作用机制,阐明FAK与VEGFR3的关系及其对淋巴管形成的调节作用;(2)研究BA抑制肿瘤细胞转移侵袭能力的分子调节机制;(3)建立人源VEGF-D/SKOV3移植瘤模型考察BA的药效。旨在为开发BA用于肿瘤治疗提供理论基础和研究新方向。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Influencing factors of carbon emissions in transportation industry based on CD function and LMDI decomposition model: China as an example

Influencing factors of carbon emissions in transportation industry based on CD function and LMDI decomposition model: China as an example

DOI:10.1016/j.eiar.2021.106623
发表时间:2021
2

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects

DOI:10.3389/fcell.2021.735374
发表时间:2021
3

Combining Spectral Unmixing and 3D/2D Dense Networks with Early-Exiting Strategy for Hyperspectral Image Classification

Combining Spectral Unmixing and 3D/2D Dense Networks with Early-Exiting Strategy for Hyperspectral Image Classification

DOI:10.3390/rs12050779
发表时间:2020
4

结直肠癌肝转移患者预后影响

结直肠癌肝转移患者预后影响

DOI:10.3969 /j.issn.1002-266X.2016.23.023
发表时间:2016
5

内质网应激在抗肿瘤治疗中的作用及研究进展

内质网应激在抗肿瘤治疗中的作用及研究进展

DOI:10.3969/j.issn.1001-1978.2021.12.004
发表时间:2021

万丽的其他基金

相似国自然基金

1

苯并吡喃酮类Akt抑制剂的设计、合成以及抗肿瘤活性研究

批准号:81001359
批准年份:2010
负责人:董晓武
学科分类:H3401
资助金额:22.00
项目类别:青年科学基金项目
2

基于苯并吡喃共轭体的比率型近红外荧光探针研究

批准号:21672080
批准年份:2016
负责人:冯国强
学科分类:B0112
资助金额:65.00
项目类别:面上项目
3

苯并异吡喃盐的串联反应和合成应用研究

批准号:21272112
批准年份:2012
负责人:姚祝军
学科分类:B0112
资助金额:80.00
项目类别:面上项目
4

苯并吡喃类化合物促进葡萄糖转运分子机理及其对II型糖尿病治疗作用研究

批准号:30472046
批准年份:2004
负责人:冷颖
学科分类:H3507
资助金额:21.00
项目类别:面上项目